The nature of immunologic tolerance /
| Main Author: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Austin :
R.G. Landes,
1994.
|
| Series: | Medical intelligence unit.
|
| Subjects: |
Table of Contents:
- History: the early years of tolerance
- Tolerance systems defined
- Properties of the unresponsive state
- Nature of the immune response
- Properties of the unresponsive state
- Systems for induction of tolerance: what do they tell us
- Sensitivity of the neonatal period to tolerance induction
- Development of T-cell tolerance in the thymus
- Differential properties of Ta dn B cells in unresponsiveness
- Role of route of exposure in tolerance induction
- Birth, death and resurrection of suppression
- T-cell tolerance to model peptides and alloantigens.
- Mechanisms of T-cell tolerance
- From horror autotoxicus to clonal deletion
- Clonal ignorance in the T-cell repertoire
- Evidence for deletion in the T-cell repertoire
- TCR transgenic mice demonstrate deletion of specific T cells
- T-cell clones can be rendered anergic by signal 1 only
- Molecular pathways of T-cell signaling to anergy
- Molecular events leading to apoptosis
- Fitting in T-cell suppression and anti-idiotype circuits
- Which mechanism where? Central versus peripheral tolerance
- Mechanisms of B-cell tolerance.
- Why do we need B-cell tolerance
- Common mechanisms for B- and T-cell tolerance
- Model systems: epitope (hapten) - specific B-cell unresponsiveness
- Anti-IgM serves as a surrogate for antigen
- Differential roles of IgM and IgD in B-cell signal transduction
- B-cell subset variations in transgenic mice
- B-cell lymphomas as a model for tolerance
- Molecular signals for the induction of tolerance in B cells
- Summary: prospects for application to clinical disease
- Immunologic misconception of birth.
- Dose and affinity are critical for tolerance induction
- Route of antigen administration is critical for successful tolerance induction
- Future therapies must consider B- versus T-cell epitopes
- Designer peptides
- Modification of proteins for reduced antigenicity and persistence in vivo
- Lack of co-stimulation
- Fusion proteins with IgG, with cytokines, and with antibodies targeting certain cells
- Maintenance of unresponsiveness: bone marrow or peripheral expression of tolerogens
- Making choices.